MPM BioImpact and Novo Holdings are among a group of investors pouring $103 million into a psychedelic biotech that MPM took private last summer.
Reunion Neuroscience, a Morristown, NJ-based biotech, unveiled its new life as a private company on Thursday morning with the Series A financing. It had originally targeted $80 million for the round, but investor interest picked up, CEO Greg Mayes told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.